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Molecular and Cellular Pathobiology
Gastrointestinal Adenocarcinomas of the Esophagus,
Stomach, and Colon Exhibit Distinct Patterns of Genome
Instability and Oncogenesis
Austin M. Dulak1,8, Steven E. Schumacher2,8, Jasper van Lieshout1, Yu Imamura1, Cameron Fox1,
Byoungyong Shim1, Alex H. Ramos8, Gordon Saksena8, Sylvan C. Baca1,6,8, Jose Baselga6,15,
Josep Tabernero13, Jordi Barretina1,3,8, Peter C. Enzinger1, Giovanni Corso14, Franco Roviello14, Lin Lin10,
Santhoshi Bandla11, James D. Luketich12, Arjun Pennathur12, Matthew Meyerson1,2,3,7,8, Shuji Ogino1,5,7,16,
Ramesh A. Shivdasani1,4,6, David G. Beer9, Tony E. Godfrey11, Rameen Beroukhim1,2,3,4,6,8, and
Adam J. Bass1,3,4,6,8
Abstract
A more detailed understanding of the somatic genetic events that drive gastrointestinal adenocarcinomas is
necessary to improve diagnosis and therapy. Using data fromhigh-density genomic profiling arrays, we conducted
an analysis of somatic copy-number aberrations in 486 gastrointestinal adenocarcinomas including 296
esophageal and gastric cancers. Focal amplifications were substantially more prevalent in gastric/esophageal
adenocarcinomas than colorectal tumors. We identified 64 regions of significant recurrent amplification and
deletion, some shared and others unique to the adenocarcinoma types examined. Amplified genes were noted in
37% of gastric/esophageal tumors, including in therapeutically targetable kinases such as ERBB2, FGFR1, FGFR2,
EGFR, andMET, suggesting the potential use of genomic amplifications as biomarkers to guide therapy of gastric
and esophageal cancers where targeted therapeutics have been less developed compared with colorectal cancers.
Amplified loci implicated genes with known involvement in carcinogenesis but also pointed to regions harboring
potentially novel cancer genes, including a recurrent deletion found in 15% of esophageal tumors where the Runt
transcription factor subunit RUNX1 was implicated, including by functional experiments in tissue culture.
Together, our results defined genomic features that were common and distinct to various gut-derived
adenocarcinomas, potentially informing novel opportunities for targeted therapeutic interventions. Cancer Res;
72(17); 4383–93. 2012 AACR.
Introduction
Colorectal, gastric, and esophageal adenocarcinomas
collectively account for approximately 180,000 cancer diagno-
ses and 76,500 deaths each year in the United States and
approximately 1.3 million deaths worldwide (1, 2). A better
understanding of the somatic genetics of these diseases is a
prerequisite for earlier diagnosis andmore effective treatment.
Colorectal cancer (CRC) genomes have been studied exten-
sively (3, 4); the value of this information is realized by
persuasive evidence that KRAS and BRAF mutations in CRC
predict lack of response to cetuximab (5, 6). Gastric cancer
(GC) and especially esophageal adenocarcinoma (EA) has been
subjected to fewer large-scale studies (7–9).
Cancers of the esophagus and stomach commonly arise in a
background of intestinal metaplasia, but develop within dis-
tinct luminal environments. Nevertheless, they often are trea-
ted with identical chemotherapy, and many clinical trials
combine patients with these 2 diseases (10, 11). Although the
process of intestinal metaplasia preceding GC and EA suggests
that these tumors may resemble adenocarcinomas arising
from the intestine, they show distinct clinical behavior from
CRC. It is therefore important to define the similarities and
differences among digestive tract adenocarcinomas at the
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genomic and molecular levels. Such a comparison can inform
both mechanistic studies and strategies for biomarker-driven
therapy.
Two challenges exist in the somatic genetic analysis of
cancer: (i) distinguishing "driver" alterations that contribute
to tumor development, maintenance, or proliferation from
random "passenger" alterations that do not contribute to the
neoplastic process, and (ii) identifying the specific genes that
mediate tumor progression. Both challenges must be con-
fronted in analysis of somatic copy-number alterations
(SCNA) as tumors often harbor many such alterations, each
of which often encompasses up to thousands of genes. The
study of SCNAs has been greatly enhanced by high-density
genomic arrays allowing resolution of individual SCNA bound-
aries and the ability to study large numbers of tumors. Statis-
tical analysis of SCNAs across many samples can identify
regions altered more frequently than expected by chance and
also pinpoint the most likely culprit genes in these regions.
Pooling data from different but related cancer types can
increase both statistical power and the ability to resolve
specific gene targets of SCNAs. Given the related origins and
documented shared copy-number characteristics of gut-
derived adenocarcinomas (12), we hypothesized that evaluat-
ing genomic events across these tumors will increase our
power to identify common genes active in gut adenocarcino-
mas and also help uncover differences. Here, we report the
largest analysis of SCNAs across gut adenocarcinoma genomes
and systematically compare significantly recurrent structural
genetic alterations in tumors from distinct regions of the gut.
We find multiple known and novel recurrent alterations,
including region-specific and shared events.
Materials and Methods
All samples were fresh frozen primary resections from
patients not treated with prior chemotherapy or radiation.
All cases had diagnoses confirmed by pathologic review and
only cases with estimated carcinoma content >70% were
selected (Supplementary Table S1). The sample set was not
enriched for other features. Tumors annotated as having
originated from the gastric–esophageal junction were
assigned to the EA collection. DNA was extracted (Supple-
mentary Table S1), quantified with Picogreen dye and
hybridized to (215 samples) GeneChip Human Mapping StyI
250K arrays (Affymetrix) or (271 samples) Genome-Wide
Human SNP Array 6.0 (SNP6.0; Affymetrix) genomic profiling
arrays, according to the manufacturer's instructions. Data
from each of the 2 array platforms were independently
normalized and segmented using all data present upon each
of the 2 platforms (12, 13). Regions of known germline copy-
number polymorphisms were then removed as previously
described (14). Human genome build hg18 was used, and raw
data files have been deposited at the Gene Expression
Omnibus (GSE36460).
Significantly recurrent SCNAs were identified using GISTIC
2.0. (15) All data from each array were used to generate SCNA
profiles for each tumor. To enable probe bound GISTIC anal-
yses across data from 2 array platforms, the segmented data
from each sample was remapped to the 196,800 probes shared
by the 2 platforms. In some cases, this remapping modified the
position of the probe bounding the transition between 2 copy-
number segments. In these cases, the boundaries were
remapped to the nearest probes in the joint set. To remove
potentially spurious SCNAs, segments defined by fewer than 9
shared probes were removed (16). Additional details are
described in Supplementary Methods.
Results
A comprehensive copy-number dataset from digestive
tract adenocarcinomas
Weanalyzed a cohort of 363 new and 123 publically available
genome array profiles from primary untreated gut adenocar-
cinomas including EA (186), GC (110), and CRC (190; Sup-
plementary Table S1). We determined genome-wide copy-
number profiles using either 250K StyI (238,000 probes) or
SNP6.0 genome arrays (1.8 million probes; Supplementary
Table S1). Copy-number alterations were identified using the
full complement of data from each array type. To enable the
analysis across platforms, the segmented copy-number data
from each sample were remapped to the 196,800 probes
common to both arrays. We found no evidence of bias intro-
duced by pooling samples from the 2 platforms (Supplemen-
tary Note S1).
Chromosomal instability increases from lower
to upper gut adenocarcinomas
Across this set of adenocarcinoma SCNA profiles, visual
inspection of the segmented data showed alterations in nearly
every part of the genome, and variations in the amount of
genomic disruption between different cancers and cancer
types (Fig. 1A). To compare levels of genomic disruption, we
separately evaluated the frequencies of arm-level (comprising
half or more of a chromosome arm) and focal SCNAs in each
cancer type. Focal alterations were noted to occur throughout
the chromosomes, but showed some predilection for the
regions closer to the centromeres and telomeres of each
chromosome (Supplementary Fig. S1).
The median number of arm-level gains varied little between
types (Fig. 1B), but was significantly increased in focal ampli-
fications in EA and GC compared with CRC (Fig. 1C). Some
tumors, particularly among CRC and GC types, showed little
apparent genomic disruption, potentially attributable to
microsatellite instability or stromal contamination (Supple-
mentary Note S2). The enhanced rate of focal amplification in
EA and GC compared with CRC remained valid when these
genomically quiet tumors were removed from analysis (Sup-
plementary Fig. S2). Upper gut adenocarcinomas exhibited
an even greater excess of higher-level, multicopy focal ampli-
fications (Fig. 1D), which remained after we accounted for
possible contaminating noncancer DNA through use of sam-
ple-specific thresholds for defining these events (Supplemen-
tary Fig. S3). The higher rates of focal genomic amplifications
in EA and GC relative to CRC suggest that underlying mechan-
isms of genomic instability may differ between upper and
lower gastrointestinal adenocarcinomas and that genomic
Dulak et al.
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amplification may be a more common means of oncogene
activation in GC/EA.
The difference in rates of focal amplifications between upper
and lower gastrointestinal adenocarcinomas did not hold for
deletions. Fewer arm-level deletionswere seen inGC thanother
gut adenocarcinomas (Fig. 1B). There was amodest increase in
focal deletions in EA compared with GC and CRC (Fig. 1B), a
trend that persisted when cases without arm-level SCNAswere
excluded (Supplementary Fig. S2). EA and CRC exhibit similar
rates of multicopy deletions that may represent homozygous
deletions, rates that are significantly higher than in GC (Fig.
1D). This pattern persisted after exclusion of "quiet" samples
and use of sample-specific thresholds to identify the multicopy
deletions (Supplementary Fig. S3). The discordant bias toward
focal amplifications but not deletions in upper gastrointestinal
cancers suggests that the mechanisms and selective pressures
leading to amplification may differ from deletion.
Recurrent amplifications and deletions across
the pooled dataset
Arm-level events. We next carried out a GISTIC 2.0 anal-
ysis to define significantly recurrent SCNAs, starting with arm-
level SCNAs. Arm-level amplifications of chromosomes 7p, 8q,
20p, and 20q recurred significantly across all 3 cancer types
(Supplementary Fig. S4A). Events restricted to specific sub-
types included 1q gains in GC and 13q gains in CRC and GC.
These significant arm-level gains have been observed pre-
viously (17–23). Arm-level deletions were more variable
across tumor types. In GC, deletions of 4p and 4q alone
were significant reflecting a lower degree of arm-level losses
detected earlier in GC (Supplementary Fig. S4B), but these
and other deletions (8p, 18p, and 18q) were also detected in
EA and CRC. Loss of arms 8p, 14q, and 15q were of higher
significance in CRC, whereas loss of 5q, 9p, and 21q were
particularly significant among EAs. Loss of 17p (containing
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Figure 1. Patterns of chromosomal instability differ across adenocarcinomas of the gastrointestinal tract. A, amplifications (red) and deletions (blue) are
displayed for 486 gut adenocarcinomas (x-axis) across the genome (y-axis). B and C, quantitation of arm-level (B) and focal (C) SCNAs. Solid bars represent
median numbers of events per sample. D, quantitation of inferred multicopy SCNAs (high-level amplifications with inferred copy >4 and presumable
homozygous deletions, inferred copy-number <1.3). , P < 0.0005; , P < 0.005; , P < 0.05; n.s., not significant.
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TP53) was significant in EA and CRC, but not GC. Unique
significant losses of 9p and 21q in EA are notable because
these arms respectively contain the known and putative
tumor suppressors CDKN2A and RUNX1, both targets of
focal deletion in EA.
These results are in accordance with previously published
data. We compared the frequency of alteration for each
cytoband in each cancer type to frequencies determined
across 998 CRC, 741 GC, and 71 EA in the Progenetix
database curated from cCGH and aCGH data (24, 25). The
cytoband-level data are similar for all cancer types, with the
exception of lower frequencies of 17q gain in our GC and EA
samples (Supplementary Fig. S5). Notably, the low frequency
of deletions in GC data compiled by Progenetix mirrored our
data suggesting that result is not unique to the samples in
our collection.
Focal alterations. We next evaluated focal SCNAs across
all 486 tumors and identified 33 regions subject to significant
(q < 0.01) focal amplification (Fig. 2 and Table 1). Thirteen of
these regions contain known oncogenes, including 4 genes
involved in cell-cycle regulation (CCNE1, CCND1, CDK6, and
MYC) and 7 members of tyrosine kinase/MAPK signaling
pathways (EGFR, KRAS, MET, ERBB2, FGFR1, FGFR2, and
IGF1R). Twenty significant peaks contained no established
oncogenes, suggesting potential presence of novel genes or
noncoding transcripts that promote intestinalmetaplasia and/
or gastrointestinal carcinogenesis.
The 18q11.2 amplification peak is the second most signif-
icant peak after KRAS and contains only the endodermal
transcription factor GATA6. Coupled with functional data
suggesting a role for GATA6 in esophageal carcinogenesis
(26, 27), these results implicate GATA6 as an important con-
tributor to gastrointestinal neoplasia. The sixth most signifi-
cant peak in the composite dataset, located at 8p23.1, contains
4 genes, including the related transcription factor GATA4, a
candidate target noted previously (28).
VEGFA* (9)
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Figure 2. Identification of significant focal SCNAs in a cohort of esophageal, gastric, and colorectal adenocarcinomas. GISTIC q-values (x-axis) for deletions
(left, blue) and amplifications (right, red) are plotted across the genome (y-axis). The 10most significant peaks are labeledwith known or putative gene targets.
Values in parentheses represent the number of genes in the peak region. , genes immediately adjacent to the peak.
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We also identified 30 regions of significant focal deletion
(Fig. 2 andTable 2). Eight of these regions include genes such as
FHIT andWWOX, with exons spread over large genomic loci
(in excess of 1 Mb). Prior studies suggest that such regions
often lie in "fragile sites" or areas of low gene density where
deletion may be tolerated, and may not harbor functional
tumor suppressors (12, 29). An additional 8 regions contain
the known tumor suppressors CDKN2A, SMAD4, PTEN, APC,
RUNX1, ARID1A, and ATM and the putative tumor suppres-
sor PARD3B (30). Fourteen regions did not contain known
tumor suppressors or large-footprint genes, but could
contain novel factors whose loss contributes to intestinal
metaplasia or cancer. Our analysis would not have detected
regions of loss of heterozygosity that did not lead to copy-
number loss.
The combined analysis across 3 tumor types enabled
identification of less common SCNAs. Five amplification
peaks were significant in the composite set but not in any
individual cancer type. One of these, 13q22.1, contains only 2
genes, including the proliferative transcription factor KLF5.
The combined dataset also enabled more precise identifi-
cation of the likely targets of focal SCNAs. For example, the
1p36.11 deletion narrowed from 89 genes in the EA set to
only 11 genes in the combined dataset, including the
Table 1. Significantly amplified focal SCNAs in a cohort of esophageal, gastric, and colorectal
adenocarcinomas (q-value <0.01)
Significant amplifications (across all gut adenocarcinomas)
Cytoband
Residual
q-value
Peak
boundaries, Mb
Number of
genes in peak Candidate target(s)
Gut adenocarcinoma
types represented
Gut adenocarcinomas
12p12.1 8.04E51 25.23–25.34 3 KRAS E, G
18q11.2 5.05E37 17.95–18.05 1 GATA6 E, G, C
17q12 4.34E35 34.97–35.27 10 ERBB2 E, G, C
19q12 5.97E34 34.95–35.10 1 CCNE1 E, G
8q24.21 8.23E34 128.50–128.83 2 MYC E, G, C
8p23.1 2.10E32 11.41–11.71 4 GATA4 E, G
11q13.2 5.26E22 68.97–69.49 5 CCND1, FGF3, FGF4, FGF19 E, G
7q21.2 3.36E17 92.32–92.50 1 CDK6* E
6p21.1 2.12E16 43.79–43.99 2 VEGFA* E, G
7p11.2 6.71E16 54.92–55.28 1 EGFR E, G
17q21.2 2.23E11 37.02–37.21 7 E
9p13.3 7.03E09 35.52–35.93 24 E
12q15 6.23E08 67.09–68.25 10 MDM2, FRS2 E, G
7q22.1 1.41E07 98.41–99.02 16 E
13q13.1 2.04E06 32.18–33.33 4 E
10q22.2 1.10E05 75.00–75.80 16 E
7q31.2 1.32E05 115.98–116.42 6 MET E
1q21.3 1.69E05 146.23–150.89 106 MCL1 E
1q42.3 1.71E04 233.02–233.42 4 G
10q26.12 3.17E04 122.75–123.37 1 FGFR2 E
13q14.11 3.67E04 40.27–40.83 10 E
13q22.1 3.90E04 72.47–73.00 2 KLF5 None
6q23.3 8.14E04 135.32–135.87 5 MYB E
7q34 1.03E03 141.92–142.26 4 EPHB6 E
8p12 1.28E03 38.23–38.46 5 FGFR1 C
3q26.2 1.55E03 169.95–175.23 32 PRKCi E
11p14.2 1.81E03 26.94–27.57 6 E
1p36.22 1.99E03 103.10–110.18 10 G
15q26.1 3.52E03 86.15–100.34 94 IGF1R None
17q24.3 4.18E03 67.82–68.05 1 SOX9 None
11q14.1 4.19E03 75.12–79.48 31 GAB2 None
20q13.2 6.89E03 51.55–52.11 3 None
3q27.1 8.69E03 185.72–186.17 3 EPHB3 G
NOTE: Bold designates therapeutic target.
*, genes immediately adjacent to the peak.
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chromatin-modifying enzyme ARID1A, a recently identified
target of frequent mutation in clear cell ovarian and gastric
adenocarcinomas (31, 32). However, combining data across
platforms also entailed some loss of resolution for the SNP6
data. We, therefore, carried out a separate analysis of the
SNP6 data, which yielded similar results to the composite
analysis, though with fewer peaks (Supplementary Note S3
and Table S6).
To identify relationships between genes targeted by focal
alterations, we evaluated the co-occurrence or exclusivity of
focal alterations at all GISTIC peak regions. After correcting for
multiple hypothesis testing and tissue type, the only significant
(Bonferroni-corrected P-value 0.05) findings were correla-
tions of amplifications of CCNE1 with each of 2 peaks with
unknown targets: a deletion peak at 6p25.3 and amplification of
1q42.3. These findings may suggest cooperativity between
these novel events and amplification of CCNE1, or reflect
subsets of tumors that for other reasons tend to share altera-
tions in these regions.
Comparison of focal alterations across gut
adenocarcinoma and other cancer types
Comparison of focal amplifications. We analyzed focal
alterations in each tumor type separately and identified 5, 14,
and 25 amplification peaks in CRC, GC, and EA, respectively
(Fig. 3A and Supplementary Fig. S6 and Table S2). Highlighting
the similarities and differences among digestive tract cancers,
only 3 amplifications were significant in all tumor types:
8q24.21 (containing MYC), 17q12 (containing ERBB2), and
18q11.2 (containing GATA6). Among these peaks, ERBB2 is
amplified more commonly in esophageal (17%) and gastric
(13%) than in colorectal (6%) tumors (Supplementary Fig. S7).
Two amplification peaks were restricted to CRCs. One
amplicon contains the RTK, FGFR1, not previously reported
Table 2. Significantly deleted focal SCNAs in a cohort of esophageal, gastric, and colorectal
adenocarcinomas (q-value <0.01)
Significant deletions (across all gut adenocarcinomas)
Cytoband
Residual
q-value
Peak
boundaries, Mb
Number of
genes in peak
Candidate
target(s)
Gut adenocarcinoma
types represented
Gut adenocarcinomas
3p14.2 1.207E313 58.98–61.52 1 FHIT E, G, C
16q23.1 2.96E151 76.69–78.21 2 WWOX E, G, C
9p21.3 5.08E56 21.98–22.01 1 CDKN2A E
20p12.1 3.22E50 14.21–15.99 2 MACROD2 E, G, C
5q11.2 9.09E38 58.30–59.84 3 PDE4D E, G, C
16p13.3 8.41E36 50.63–77.09 2 A2BP1 C
6p25.3 2.09E28 1.54–2.57 2 E, G
4q22.1 2.60E27 91.37–93.49 2 FAM190A E, G, C
6q26 3.61E21 161.61–163.13 1 PARK2 E, G, C
9p24.1 1.32E14 7.77–12.71 3 PTPRD E, G
18q21.2 7.52E14 46.77–46.97 1 SMAD4 E, C
1p36.11 1.36E11 26.77–27.31 11 ARID1A E, C
21q11.2 1.61E06 1.00–1.64 17 E
1q44 2.64E06 24.39–24.48 1 E
8p23.3 2.64E06 1.00–1.71 7 E
10q23.31 2.64E06 89.44–90.07 4 PTEN C
21q22.12 5.76E06 35.03–35.35 2 RUNX1 E
4q35.1 1.80E05 179.06–187.23 31 E
7q36.3 3.01E05 156.49–158.82 12 E
5q22.2 5.22E05 110.88–113.74 12 APC C
1p13.2 8.53E05 111.01–119.86 79 C
2q33.2 1.15E04 204.53–206.27 1 PARD3B E
3p26.2 1.24E04 4.32–4.51 1 None
4q35.2 4.15E04 185.37–191.27 36 CASP3 C
17p12 1.38E03 11.40–12.51 5 None
11q22.3 2.26E03 103.49–112.70 62 ATM E
5q15 3.85E03 83.69–106.74 56 None
21q22.3 8.17E03 38.21–46.94 116 None
12q21.2 8.88E03 71.30–86.91 39 None
10q11.23 9.24E03 52.31–53.77 5 C
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in this disease, but noted to be overexpressed (33). The other
unique peak is adjacent to the CRC oncogene CDK8 at 13q12.2
(34). Esophageal and gastric adenocarcinomas shared 7 ampli-
cons, containingVEGFA,EGFR,GATA4,CCND1,MDM2,CCNE1,
and KRAS. The most significantly amplified gene across our
dataset, KRAS, showed a strong foregut preference. Only 5% of
CRCs carried focal KRAS amplification, compared with 21% of
upper GI cancers. Conversely, CRCs have substantially higher
rates of KRAS mutation (Supplementary Fig. S8) showing how
upper and lower gastrointestinal cancers show distinct ways of
altering the same oncogene (35).
An additional 14 regions of amplificationwere specific to EA.
Six of these peaks contained genes known to contribute to
cancer (CDK6,MCL1, PRKCI,MYB,MET, and FGFR2), although
the others contain no previously described oncogenes. To
evaluate how the large sample size enabled identification of
relevant targets, we compared our analysis to the SCNA
analyses of the largest previously published EA datasets, com-
prising 42 and 56 tumors (8, 36). Amplifications at CCNE1,
MET, FGFR2, and MYB were not identified in previous
datasets, but these genes have been noted to be overex-
pressed in EA (37–40). Many peaks that lack known onco-
genes were also not noted in earlier reports. Although MET
and CCNE1 amplifications had been detected previously by
focused gene inquiry, MYB and FGFR2 amplifications were
not noted in prior data. Our sample numbers also afforded
greater resolution to identify targets of previously identified
SCNAs. For example, an amplicon at 6p21.1 was reported in
studies of 42 and 56 EAs to contain between 50 and 70 genes
(8, 36). We narrowed this region to only 2 genes, including
the vascular endothelial growth factor, VEGFA, the target of
the therapeutic antibody bevacizumab. A prior study of EA
also identified a 94-gene region of amplification on 3q and
attributed this event to PIK3CA (36). Our analysis narrows
this peak to a region containing PRKCI, >5 Mb away from
PIK3CA.
The presence of FGFR2 amplifications in EA suggests a
potential new therapeutic target for these tumors, similar to
in GC (9). We confirmed the presence of FGFR2 amplification
in individual EA cases through quantitative RT-PCR (Supple-
mentary Fig. S9). These results indicate FGFR2 amplification
may serve as a biomarker for the use of FGFR2-directed therapy
in EA in addition to GC.
Four amplification peaks were restricted to gastric adeno-
carcinoma. Among these, only 3q27.1, containing the RTK
gene, EPHB3, has been suggested to play a role in cancer
progression (41). Compared with prior studies, we not only
confirmed recurrent focal amplifications involving GATA4 and
GATA6, but also identified novel peaks on 6p21.1 (VEGFA),
3q27.1 (EPHB3), 1p36.22, 12q15, and 1q42.3 (9).
The most significant focally amplified tyrosine kinases,
ERBB2, EGFR, MET, FGFR1, and FGFR2, are known oncogenes
and targets of therapeutic agents in current use or development.
We detected amplifications involving one or more RTKs in 42%
of EA, 28% of GC, and 14% of CRC samples (Fig. 4). Only 10% of
tumors had concurrent amplifications of RTKs and KRAS.
Finally, we compared amplifications in GI adenocarcinomas
to those found in a study of 2,311 diverse cancers (12). Among
the 33 focal amplifications in GI cancers, 42% overlapped with
peak regions in other cancers (Supplementary Fig. S10), includ-
ing 11 regions containing the known oncogenes MCL1, MYB,
EGFR, FGFR1, MYC, CCND1, KRAS, MDM2, ERBB2, and CCNE1
(marked with asterisks in Fig. 3). Peak regions present in gut,
but absent from nongut adenocarcinomas, encompassed
genes encoding the tissue-specific transcription factorsGATA4
and GATA6 and the known or putative oncogenes CDK6,
FGFR2, MET, EPHB3, and EPHB6. Some of these genes are
occasionally amplified in other cancer types, but did not
show statistical significance. HMGA2 amplifications on chro-
mosome 12 are notably absent in GI tumors, despite the
presence of chromosome 12 amplification at MDM2 in both
GI and non-GI carcinomas. Similarly, amplification of the
G1–S cell-cycle–dependent kinase CDK6 is restricted to GI
tumors, whereas CDK4 amplification is significant in all other
tumors further suggesting that many cancer use similar path-
ways with multiple inputs to reach the same output (Supple-
mentary Table S3).
Comparison of focal deletions. We identified 16, 8,
and 21 peaks of significant deletion in CRC, GC, and EA,
respectively (Fig. 3B and Supplementary Fig. S11 and Table
S4). Six peaks were shared across the 3 cancer types, all con-
taining genes spanning large genomic loci (including FHIT,
WWOX, and MACROD2; refs. 12, 42).
Seven deletion peaks were unique to CRC, including 2 peaks
that encompass known tumor suppressors (APC and PTEN),
and 5 that do not. Among the latter, a previously unidentified
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Figure 3. Venn diagram of focal events common across gut
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peak at 10q25 contains the apoptosis effector caspase gene
CASP7, suggesting a mechanism to evade apoptosis (Supple-
mentary Table S4A).
Eleven deletion peaks were unique to EAwhereas none were
unique to GC (Fig. 3B). Among the EA peaks, 2 contain known
esophageal tumor suppressors (CDKN2A and ATM; Supple-
mentary Table S4B and Fig. S7D). One peak contains RUNX1,
which we consider further below. Two peaks were seen in both
esophageal and gastric tumors, including 1 large gene (PTPRD)
and 1 region (6p25.3) with no known tumor suppressor.
Among the 30 deletion peaks in the composite tumor set
(Table 2), 15 were also significant in the non-GI adenocarci-
noma study (Supplementary Fig. S10). The common sites
included 9 peaks encompassing large genes, 4 peaks containing
known deleted tumor suppressors (APC, CDKN2A, ATM, and
PTEN), and 2 peaks without either. One of the latter peaks
contains the effector caspase gene CASP3, suggesting that
deletion of an effector caspase, CASP3 or CASP7, may mark
GI adenocarcinomas more generally and not CRC alone. Focal
loss of RB1 and TP53 were identified in non-GI but not in
digestive tract adenocarcinomas, although 17p deletion, con-
taining TP53, was significant in CRC and EAC. The 15 deletion
peaks restricted to GI adenocarcinomas include 13 that lack
known tumor suppressors (Supplementary Table S5). The
other 2 contain the known tumor suppressors SMAD4 and
RUNX1.
Functional significance of RUNX1 deletions
in esophageal adenocarcinoma
We observed highly focal RUNX1 deletions at 21q22.12 in
15% of EAs, also noted in a recent report (Fig. 5A; ref. 36).
RUNX1 behaves as a tumor suppressor in leukemia, where
translocations and mutations disrupt gene function (43). We,
therefore, evaluated a possible tumor suppressor function for
RUNX1 in EA by reintroducing it into the EA cell line OE33,
which carries a focal RUNX1 deletion (Fig. 5A). We observed a
69% reduction in anchorage-independent growth relative to
GFP-infected cells (Fig. 5B and C). As we did not possess an EA
cell line without deletion at the RUNX1 locus, we ectopically
expressedRUNX1 in A549 lung cancer cells, which have no focal
RUNX1 deletion, to evaluate for generalized cellular toxicity
because of overexpression of this gene. In contrast to OE33
cells,RUNX1 expression did not significantly affect A549 colony
formation (Fig. 5B and C). These results are consistent with a
potential role for RUNX1 as a tumor suppressor in EA.
Discussion
These data provide the most comprehensive, high-resolu-
tion analysis to date of SCNA patterns across the 3 most
common forms of gut adenocarcinoma. Our cohort size
enhanced the ability to detect significant SCNAs, and we
identified several focused areas of recurrent genomic alter-
ation pointing toward genes that may contribute to cancer.
Notably, the genomes of EA andGC cancers contain alterations
selected for their contributions to the process of both intestinal
metaplasia andmalignant transformation to adenocarcinoma.
We observed more focal amplifications in upper GI adeno-
carcinomas compared with CRC. Unlike CRC, EA, and GC
emerge in a setting of bile and acid injury, which may generate
DNA strand breaks and contribute to the high rates of SCNA
(44). Alternatively, distinct DNA repair pathways or selection
for differing stimuli may account for these differences. It is
unclear why the enhanced rates of focal amplifications in EA/
GC were not matched by a similarly increased rate of focal
deletions nor why the rates of deletion in GC fell below those in
EA or CRC. Although, the loci of the most significant ampli-
fications peaks fell at known or plausible oncogenes, many
focal deletions peaks lie in potential fragile sites. Thus, the
mechanisms and selection pressures underlying deletionsmay
differ from those responsible for amplification.
The GATA6 and GATA4 transcription factor genes lie in the
second and sixth most significant amplification peaks across
the full dataset, respectively. The developmental role of these
Esophageal Gastric Colon
58% %27%24 %68%82 14%
MET
FGFR1
FGFR2
ERBB2
EGFR
Figure 4. Amplified therapeutic
determinants in gut adenocarcino-
mas. The presence of focal
amplifications (inferred copy
number > 2.3) is shown in red for
recurrently amplified receptor
tyrosine kinase genes across all
tumor specimens (vertical bars).
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transcription factors and selective amplification in GI cancers
suggests that they may add to the growing number of lineage-
survival transcription factor oncogenes (45). A parallel phe-
nomenon is amplification of SOX2 in squamous esophageal
and lung carcinomas (46), an event absent in EA.
A key clinical observation emerging from these data is that
focally amplified RTKs were observed most prominently in EA
and GC, suggesting that genomic amplifications will be more
important biomarkers in upper gastrointestinal cancers than
in CRC. Recent clinical trials reveal benefit when the HER2-
directed antibody trastuzumab is combined with chemother-
apy in treating ERBB2-amplified or overexpressing GC/EA (11).
The presence of ERBB2 amplifications in 6% of CRCs suggests
that ERRB2 (HER2)-directed therapy may benefit select
patients with CRC (47). In addition, based on evidence that
KRASmutation negatively predicts cetuximab response, highly
prevalentKRAS amplification in upperGI tumorsmay similarly
impact clinical decisions. When KRAS is evaluated as a bio-
marker in upper GI cancers, it will be important to examine
both SCNAs and point mutations. Our data also point to other
genomic amplifications of clinical relevance. CDK6 (48) and
VEGFA focal amplifications may serve as a marker of response
to targeted inhibitors. More broadly, these data point to the
inclusion of gene amplifications to guide therapy in upper
gastrointestinal adenocarcinomas.
Although these data suggest that many patients with EA or
GC may benefit from treatment targeting an amplified RTK, it
is unlikely that therapies directed against these targets alone
will lead to durable responses. The progression-free survival
provided by single-agent therapy with trastuzumab in GC/EA
has been modest (11). The presence of complex SCNA profiles
in these tumors suggest there could be co-occurring alterations
that confer primary resistance (49) or enhanced genomic
instability that speeds acquired resistance. In our cohort, the
rates of co-occurrence between RTK-associated and other
events did not significantly deviate from what would be
expected for statistically independent events. However, co-
occurrences were detected, and the rateswithwhich individual
pairs of events co-occur are likely to inform combinational
treatment strategies. Although evaluation of RTK-targeted
agents is needed, the genomic complexity and variability of
these cancers suggests that combination inhibitor strategies
will ultimately be essential.
Beyond these immediately clinically relevant targets, these
data provide enhanced insight into specific genes responsible
for different subtypes of gastrointestinal adenocarcinomas.
Despite a shared intestinal origin, upper gastrointestinal can-
cers exhibit many distinct events from those seen in CRC, such
as alteration of cell-cycle regulators (CCND1, CCNE1, CDK6,
and CDKN2A). Moreover, as evidenced by the selective deletion
of RUNX1 in EA, clear genomic differences exist between EA
and GC. Although our analysis has helped identify loci of
recurrent alteration andpotential targets of these events,many
recurrent regions of SCNA do not contain known oncogenes or
tumor suppressors. One challenge moving forward will be to
determine which of these regions harbor additional genes or
noncoding elements that contribute toward intestinal meta-
plasia or transformation to cancer. High-resolution genome
analyses of large sample numbers, as presented here, can guide
future studies and inform the development of strategies to
Figure 5. RUNX1 reexpression
can inhibit anchorage-independent
growth in an esophageal
adenocarcinoma cell model. A, focal
deletion of locus 21q22.12
containing RUNX1 in esophageal
adenocarcinomas, OE33 (EA), and
A549 (non–small cell lung cancer) cell
lines. B, OE33 and A549 cell lines
were stably transduced with
retrovirus containing RUNX1.
Immunoblotting confirmed positive
expression of RUNX1. C, soft agar
colony formation for OE33 and A549
cells with ectopic GFP or RUNX1
expression. Representative images
of colony formation at 6.3
magnification. Quantitation of 3
independent experiments; error bars
represent SEM. , P < 0.005; n.s.,
not significant.
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reverse the effects of the somatic genetic events that drive
these cancers.
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